Literature DB >> 30746576

Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.

Tycho Heimbach1, Sandra Suarez-Sharp2, Maziar Kakhi2, Nico Holmstock3, Andrés Olivares-Morales4, Xavier Pepin5, Erik Sjögren6,7, Eleftheria Tsakalozou2, Paul Seo2, Min Li2, Xinyuan Zhang2, Ho-Pi Lin2, Timothy Montague8, Amitava Mitra9, Denise Morris10, Nikunjkumar Patel11, Filippos Kesisoglou12.   

Abstract

This publication summarizes the proceedings of day 2 of a 3-day workshop on "Dissolution and Translational Modeling Strategies Enabling Patient-Centric Product Development." Patient-centric drug product development from a drug product quality perspective necessitates the establishment of clinically relevant drug product specifications via an in vitro-in vivo link. Modeling and simulation offer a path to establish this link; in this regard, physiologically based modeling has been implemented successfully to support regulatory decision-making and drug product labeling. In this manuscript, case studies of physiologically based biopharmaceutics modeling (PBBM) applied to drug product quality are presented and summarized. These case studies exemplify a possible path to achieve an in vitro-in vivo link and encompass (a) development of biopredictive dissolution methods to support biowaivers, (b) model-informed formulation selection, (c) predicting clinical formulation performance, and (d) defining a safe space for regulatory flexibility via virtual bioequivalence (BE). Workflows for the development and verification of absorption models/PBBM and for the establishment of a safe space using dissolution as an input are described with examples. Breakout session discussions on topics, such as current challenges and some best practices in model development and verification, are included as part of the Supplementary material.

Entities:  

Keywords:  IVIVC/IVIVR; clinically relevant dissolution specifications; physiologically based biopharmaceutics modeling (PBBM); safe space; virtual bioequivalence

Mesh:

Substances:

Year:  2019        PMID: 30746576     DOI: 10.1208/s12248-019-0298-x

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  11 in total

1.  Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.

Authors:  Fang Wu; Heta Shah; Min Li; Peng Duan; Ping Zhao; Sandra Suarez; Kimberly Raines; Yang Zhao; Meng Wang; Ho-Pi Lin; John Duan; Lawrence Yu; Paul Seo
Journal:  AAPS J       Date:  2021-02-22       Impact factor: 4.009

2.  A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms.

Authors:  Nan-Hung Hsieh; Frédéric Y Bois; Eleftheria Tsakalozou; Zhanglin Ni; Miyoung Yoon; Wanjie Sun; Martin Klein; Brad Reisfeld; Weihsueh A Chiu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-09-22       Impact factor: 2.410

Review 3.  Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.

Authors:  Di Wu; Min Li
Journal:  Pharm Res       Date:  2022-09-08       Impact factor: 4.580

Review 4.  Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1.

Authors:  Eleftheria Tsakalozou; Andrew Babiskin; Liang Zhao
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-03-09

Review 5.  In Silico Modeling and Simulation to Guide Bioequivalence Testing for Oral Drugs in a Virtual Population.

Authors:  Fan Zhang; Ranran Jia; Huitao Gao; Xiaofei Wu; Bo Liu; Hongyun Wang
Journal:  Clin Pharmacokinet       Date:  2021-06-30       Impact factor: 5.577

Review 6.  Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches.

Authors:  David Dahlgren; Hans Lennernäs
Journal:  Pharmaceutics       Date:  2019-08-13       Impact factor: 6.321

7.  Developing Clinically Relevant Dissolution Specifications for Oral Drug Products-Industrial and Regulatory Perspectives.

Authors:  Mark McAllister; Talia Flanagan; Karin Boon; Xavier Pepin; Christophe Tistaert; Masoud Jamei; Andreas Abend; Evangelos Kotzagiorgis; Claire Mackie
Journal:  Pharmaceutics       Date:  2019-12-23       Impact factor: 6.321

8.  Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.

Authors:  Emma Eckernäs; Christer Tannergren
Journal:  Mol Pharm       Date:  2021-03-15       Impact factor: 4.939

Review 9.  Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on in vivo data from intestinal perfusion models.

Authors:  David Dahlgren; Erik Sjögren; Hans Lennernäs
Journal:  ADMET DMPK       Date:  2020-09-17

10.  A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP.

Authors:  Marival Bermejo; Bart Hens; Joseph Dickens; Deanna Mudie; Paulo Paixão; Yasuhiro Tsume; Kerby Shedden; Gordon L Amidon
Journal:  Pharmaceutics       Date:  2020-01-17       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.